Introduction In 2003, the World Health Organization (WHO) defined the neuroendocrine breast carcinoma (NEBC) as a subtype of invasive mammary carcinoma in which 50% of the tumor cells express neuroendocrine markers; immunohistochemical staining include chromogranin, synaptophysin, and neurospecific enolase (NSE). The reported incidence is 2%-5%, accounting for 0.1% of all breast cancers and 1% of all neuroendocrine tumors. We report 4 cases of primary NEBC, describing the histopathological features of NEBC, and giving some future challenges of this entity.